The companies will collaborate to develop a digital health ecosystem for allergen immunotherapy treatment
Aptar Pharma, a provider of drug delivery systems and active material science services, has announced a partnership with Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), for the development of a connected drug delivery device and companion mobile app for patients undergoing Stallergenes Greer’s AIT treatments with sublingual solutions.
Non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management. The connected device is designed to improve dose compliance and adherence, thus optimising patient treatment outcomes.
This partnership underlines Aptar’s progress in the field of digital therapeutics, with the development work being undertaken by its Digital Health Group, which provides a full turnkey solution that includes device and software development expertise. The product will leverage the company’s Cohero platform, which will be tailored specifically for this use.
“We are pleased to combine Aptar Pharma’s Digital Health ecosystem with Stallergenes Greer’s knowledge and leading position in AIT to further improve the treatment journey of patients who suffer from allergies,” said Sai Shankar, VP, Global Digital Healthcare Systems, Aptar Pharma.
“This exclusive partnership with Aptar Pharma demonstrates the intensification of Stallergenes Greer’s investments in innovation to provide a large range of precise personalised allergen immunotherapy options adapted to the individual needs and lifestyle of patients. Stallergenes Greer is well advanced on its digital transformation journey and will continue to develop its e-health offering for the benefit of all stakeholders,” said Dominique Pezziardi, General Manager France, Belgium & Luxembourg, Global Head of Pricing and Market Access, Stallergenes Greer.
The connected device and mobile app, part of Aptar’s portfolio of digital healthcare solutions, should be available in France in 2022 and will be progressively rolled-out in Stallergenes Greer’s markets.